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 Abstract 
Kisspeptins are G protein-coupled receptor ligands originally identified as 
human metastasis suppressor gene products that have the ability to suppress 
melanoma and breast cancer metastasis and recently found to play an important role 
in initiating the secretion of gonadotropin-releasing hormone at puberty.  Kisspeptin-
13 is an endogenous isoform that consists of 13 amino acids.  
The action of kisspeptin  in  the regulation of gonadal function  has been widely 
studied,  but little is known as concerns its  function  in limbic brain  structures. 
 In the brain,  the gene is transcribed within the hippocampal dentate gyrus. 
This paper reports on  a study the effects  of kisspeptin-13 on passive avoidance 
learning and the involvement of the adrenergic, serotonergic, cholinergic, 
dopaminergic and GABA-A-ergic, opiate receptors and nitric oxide in its action in 
mice. Mice were pretreated with a nonselective α-adrenergic receptor antagonist, 
phenoxybenzamine, an α2-adrenergic receptor antagonist, yohimbine, a β-adrenergic 
receptor antagonist, propranolol, a mixed 5-HT1/5-HT2 serotonergic receptor 
antagonist, methysergide, a nonselective 5-HT2 serotonergic receptor 
antagonist, cyproheptadine, a nonselective muscarinic acetylcholine receptor 
antagonist, atropine, D2,D3,D4 dopamine receptor antagonist, haloperidol, a γ-
aminobutyric acid subunit A (GABAA) receptor antagonist, bicuculline, naloxone, a 
nonselective opioid receptor  antagonist and  nitro-L-arginine, a nitric oxide synthase 
inhibitor. Kisspeptin-13 facilitated  learning and  memory consolidation in a passive 
avoidance paradigm.  Phenoxybenzamine, yohimbine, propranolol,  methysergide, 
cyproheptadine, atropine, bicuculline and nitro-L-arginine prevented the action 
of kisspeptin-13 on  passive avoidance learning, but haloperidol and naloxone  did 
not change the effects of kisspeptin-13. The results demonstrated that the action 
of kisspeptin-13  on the facilitation of passive avoidance learning and memory 
consolidation  is mediated, at least in part, through   interactions  of the α2-
adrenergic, beta-adrenergic, 5-HT2 serotonergic, muscarinic cholinergic and  GABA-
A-ergic  receptor systems  and nitric oxide. 
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1. Introduction 
     Kisspeptin (KP), formerly known as metastin, was originally identified as a human 
metastasis suppressor that inhibits the metastasis of melanoma and breast cancer 
[1].  This G protein-coupled receptor ligand was recently found to play  important 
roles  in the maturation and functioning   of the  reproductive axis, including the 
sexual differentiation of the brain, the timing of puberty, the regulation of the  
gonadotropin-releasing hormone (GnRH) at puberty, and the control of fertility by 
metabolic and environmental cues [2].  KP-13, one of the endogenous isoforms, 
consists of 13 amino acids [3]. In the central nervous system, KP is transcribed within 
the hippocampal dentate gyrus [4-6]. Little is known concerning the mechanisms and 
pathways of the action of KP-13 on the brain functions.  We recently reported that 
KP-13 elicits antidepressant action in a  forced swimming test in mice [7]. 
However no data have  been published regarding the action of kisspeptin-13 on the 
cognitive function. 
     In the present investigation, the effects of KP-13 were studied on passive 
avoidance learning and the potential involvement of the adrenergic, serotonergic, 
cholinergic, dopaminergic and gabaergic, opiate and nitric oxide receptors in mice. 
Mice were pretreated with a nonselective α-adrenergic receptor antagonist, 
phenoxybenzamine,  an α2-adrenergic receptor antagonist, yohimbine, a β-
adrenergic receptor antagonist, propranolol, a mixed 5-HT1/5-HT2 serotonergic 
receptor antagonist, methysergide, a nonselective 5-HT2 serotonergic receptor 
antagonist, cyproheptadine, a nonselective muscarinic acetylcholine receptor 
antagonist, atropine,a  D2,D3,D4 dopamine receptor antagonist, haloperidol, or a γ-
aminobutyric acid subunit A (GABAA) receptor antagonist, bicuculline, naloxone, a 
nonselective opioid receptor  antagonist, and   a nitric oxide synthase inhibitor, nitro-
L-arginine. 
2. Materials and methods 
2.1. Animals 
     CD1 (Charles Dawley) male mice (Bioplan Isaszeg, Hungary) were kept and 
handled during the experiments in accordance with the instructions of the University 
of Szeged Ethical Committee for the Protection of Animals in Research. Each animal 
was used in the experiments only once. The animals were six week old, weighed 
between 28- 35 g. They were housed in cages (5 animals/cage) in a room maintained 
at constant temperature (25 ± 1 °C) and on a 12-h d ark–light cycle (lights on at 
06:00–18:00 h) with free access to tap water and standard laboratory food. One 
week of recovery from surgery was allowed before the experiments. 
2.2. Surgery 
     The mice were anesthetized with sodium pentobarbital (Nembutal 35 mg/kg i.p.) 
implanted with a cannula introduced into the right lateral brain ventricle in order to 
allow intracerebroventricular (i.c.v.) administration. The polystyrene cannula was 
inserted stereotaxically into the ventricle at the coordinates 0.2 mm posterior, 0.2 mm 
lateral to the bregma, and 2.0 mm deep from the dural surface . The cannula was 
secured with cyanoacrylate (Ferrobond) (Budapest, Hungary). The mice were 
allowed  7 days to recover from surgery before any i.c.v. administration. The correct 
location of the cannula was checked by dissecting the brain following completion of the 
experiments. Only animals with the correct location of the cannula were used in the 
evaluation of the experiments. All experiments were performed in the morning period.  
                                  
2.3. Drugs  
     KP-13 was from Bachem (Basel, Switzerland); phenoxybenzamine hydrochloride 
from Smith Kline & French (Herts, UK); yohimbine hydrochloride from Tocris 
(Cologne, Germany); propranolol hydrochloride from ICI Ltd. (Macclesfield, UK); 
methysergide hydrogenmaleate from Sandoz (Cologne, Germany); cyproheptadine 
hydrochloride from Tocris (Bristol, UK); atropine sulfate from EGYS (Budapest, 
Hungary); haloperidol from G. Richter (Budapest, Hungary); and bicuculline 
methiodide from Sandoz (Basel, Switzerland). Nitroω-L-Arginine methylester 
hydrochloride (Sigma St Louis USA). Naloxone hydrochloride (Endo Labs, 
Wilmington USA). 
     KP-13 was lyophilized in a quantity of 10 µg per ampoule and stored at −20 °C. 
Immediately before the experiments, the KP-13 was dissolved in sterile pyrogen-free 
0.9% saline and administered i.c.v. via the cannula in a volume of 2 µl. 
2.4. Treatments 
 
     For the  i.c.v administration of  kisspeptine-13 and nitro-L arginine, the  previously  
inserted polystyrene canulla was used 
     The receptor blockers were dissolved in 0.9 % saline and were administered 
intraperitoneally (i.p.). The effective doses of the receptor antagonists were selected 
on the basis of  previous experiences in which   the minimal doses were effective (in 
other tests), but did not themselves influence the tests [7,8]. The receptor blockers 
were administered Immediately following the learning trial i.p and 30 min later the 
Kisspeptin-13, the control mice were treated with 0.9% saline (on each occasion with 
2 µl  i.c.v).  Immediately following the learning trial,  the kisspeptin-13   group was 
treated with 0.9% saline (2 µl/ i.c.v) which was  followed 30 min  later by kisspeptin-
13  (1 µg/2 µl i.c.v).  All groups were  tested  at  24 h.  The same protocol was 
followed in all treated groups. For the combined treatment of kisspeptin-13 and 
antagonists, only the most effective dose (1 µg/2 µl) was used (see dose-response in 
kisspeptin-13 treatment).  
2.5. Behavioral testing 
 
 Passive avoidance test  
   
    One-trial learning, step-through passive avoidance behavior was measured 
according to Ader et al.(1972) [9] in Ugo Basile passive avoidance apparatus (Italy.) 
Briefly, mice were placed on an illuminated platform and allowed to enter a dark 
compartment. Since mice prefer dark to light, they normally entered within 5 s. Two 
additional trials were delivered on the following day. After the second trial, unavoidable 
mild electric footshocks (0.75 mA, 2 s) were delivered through the grid floor. Having 
entered the box, the animals could not escape the footshock. After this single trial, the 
mice were immediately removed from the apparatus and were treated. The 
consolidation of passive avoidance behavior was tested 24 h later. In the 24-h testing, 
each animal was placed on the platform and the latency to enter the dark 
compartment was measured up to a maximum of  300 s.  
2.6. Statistical analysis 
    The analysis of variance (two-way ANOVA) test was followed by Tukey’s test for 
multiple comparisons with unequal cell size using Origin  7.5 software. Probability 
values (P) of less than 0.05 were regarded as indicative of significant differences. 
3. Results 
     Kisspeptin-13 in a dose of 0.5 and 2  µg/2 µl)  i.c.v. had no action on the 
consolidation of  passive avoidance learning, while 1 µg i.c.v. significantly facilitated 
the consolidation of passive avoidance memory [F(3,18)= 22.52]; p<0.05 (Fig. 1).   
     In the phenoxybenzamine-pretreated group, kisspeptin-13 (1 µg/2 µl i.c.v.) 
facilitated the consolidation of passive avoidance learning [F(3,18)=4.03]; p<0.05.  
Phenoxybenzamine (2 mg/kg i.p.) itself had no action, but fully blocked the action of 
kisspeptin-13 (Fig. 2). 
     In the yohimbine pretreated group yohimbine (0.5 mg/kg i.p.) itself had no action, 
while fully blocked the action of kisspeptin-13 (1 µg/2 µl i.c.v) [F( 3,35)=3.83],p<0.05 
(Fig.3). 
    In the propranolol-pretreated group kisspeptin-13 (1 µg/2 µl i.c.v.) facilitated the 
consolidation of passive avoidance learning [F(3,20=4.03], p<0.05. Propranolol (10 
mg/kg i.p.) itself had no action,  however fully blocked the action of kisspeptin-13. 
(Fig.4).  
    In the methysergide-pretreated group, kisspeptin-13 (1 µg/2 µl i.c.v.) facilitated the 
consolidation of passive avoidance learning.[F(3,20)=8.67), p<0.05. Methysergide (5 
mg/kg i.p.) alone had no action in the doses used, but fully blocked the action of 
kisspeptin (Fig.5.). 
    In the cyproheptadine-pretreated group, kisspeptin-13 (1 µg/2 µl i.c.v.) facilitated 
the consolidation of passive avoidance learning  [F(3,20)=12.27]; p<0.05. 
Cyproheptadine (3 mg/kg i.p.) itself had no action, but fully blocked the action of 
kisspeptin-13 (Fig. 6). 
    In the atropine-pretreated group, kisspeptin-13 (1µg/2 µl i.c.v.) facilitated the 
consolidation of passive avoidance learning [F(3,18)=4.68];p<0.05. Atropine (2 mg/kg 
i.p.) itself had no action, but fully blocked the action of kisspeptin-13 (Fig. 7). 
    In the haloperidol-pretreated group, kisspeptin-13 (1 µg/2 µl i.c.v.) facilitated the 
consolidation of passive avoidance learning [F(3,19)=4.34];p<0,05. Haloperidol (10 
µg/kg i.p.) itself had no  action,  attenuated but did not  fully block the action of 
kisspeptin-13 (Fig. 8). 
    In the bicuculline-pretreated group, kisspeptin-13 (1 µg/2 µl i.c.v.) facilitated the 
consolidation of passive avoidance learning. [F(3,20)=21.02] ; p<0.05. Bicuculline (2 
mg/kg i.p.) itself had no action, but fully blocked the action of kisspeptin-13 (Fig. 9). 
    In the naloxone-pretreated group  kisspeptin-13 (1 µg/2 µl i.c.v.) facilitated the 
consolidation of passive avoidance learning.[F(3,20)=17,20 ;P<0.05.  Naloxone 0.3 
mg/kg i.p) had no action on kisspeptin-13 induced facilitation of passive avoidance 
learning (Fig. 10) 
    In the nitro-L-arginine- pretreated group, kisspeptin-13 (1 µg/2 µl i.c.v.) facilitated 
the consolidation of passive avoidance learning [F(3,19=7.09)] ; p<0.05. Nitro-L-
arginine (10  µg/2 µl i.c.v.) itself had no action, but  blocked the action of kisspeptin-
13 (Fig.11). 
     
4. Discussion 
     In the central nervous system, KP-expressing neurons are located in the 
anteroventral periventricular nucleus (AVPV), the periventricular nucleus (PVN), the 
anterodorsal preoptic nucleus and the arcuate nuceus (Arc) [10].  In close 
relationship with the PVN, the neurons of the AVPV and Arc project fibers into the 
preoptic area rich in GnRH cell bodies.  It is now known that KP stimulates the 
secretion of GnRH, which is sensitive to steroid levels [3]. 
     A number of excellent reviews have summarized the  role of KP in the regulation  
of  the reproductive function, concentrating mainly on the hypothalamus.[11-19],  but 
little is known as regards its in  limbic brain areas outside  the hypothalamusIn the 
central nervous system, KP is transcribed within the hippocampal dentate gyrus  [5-
6].  KP-13, one of the endogenous isoforms, consists of 13 amino acids [3]. KP1r has 
been found in the amygdala and hippocampus [13, 20-24] and the bed nucleus of the 
stria terminalis  [25], and  is expressed in the granular cells  of the dental gyrus  
[20],and KP treatment increases the excitability  of these cells [4-6]. 
     A few data indicate that KP has other actions   besides that on   reproduction. The 
hyperalgesic action of KP has been reported in mice [26].  KP directly regulates  
neuropeptide Y synthesis in hypothalamic neurons  [27]. Central administration of KP 
reduces the  food intake [28]. KP-10 evoked a dose-dependent increase in edema 
formation and led to microvascular constriction  in the cutaneous vasculature [29].  
     Central administration of KP-10 also inhibits sodium excretion and the urine flow,  
presumably by increasing the plasma vasopressine concentration [30]. 
     The interaction of kisspeptin with other neurotransmithers  has  been reported. 
KP  excites anorexigenic pro-opiomelanocortin neurons but inhibits orexigenic 
neuropeptide Y cells  by enhancing GABA-mediated inhibition [31]. 
KP neurons co-express met-enkephalin and galanin in the periventricular region of 
the female mouse hypothalamus [32]. 
     It has been  suggested that KP may play a role  in various neurological processes 
apart from reproduction, such as  cognitition and epilepsy [6], and presumably in 
some so far unkown central nervous action (e.g. Oklay 2009, [33] ). 
     We have demonstrated that KP-13 elicits antidepressant action in a modified 
forced swimming test in mice. This action  is mediated by an interaction of α2-
adrenergic and 5HT2 serotonergic receptors [7]. 
     The present study related to   the  action of KP-13 on passive avoidance learning  
and  the possible involvement of neurotransmitters in this action. To clarify the 
mechanisms of action of  KP-13 on passive avoidance learning, various receptor 
blockers were applied before KP-13 administration. The receptor blocker doses were 
selected so that the blockers per se were ineffective, but were able to block the 
action of a neuropeptide as described previously [7,8]. The findings observed with 
the receptor blockers indicated that the action of KP-13 is mediated by  a number of  
receptors. 
     The nonselective α-adrenergic receptor antagonist phenoxybenzamine, the α2-
adrenergic receptor antagonist yohimbine, the nonselective 5-HT2 serotonergic 
receptor antagonist cyproheptadine. the β-adrenergic receptor antagonist 
propranolol, the mixed 5-HT1/5-HT2 serotonergic receptor antagonist methysergide,   
the nonselective muscarinic acetylcholine receptor antagonist atropine, and the 
GABAA receptor antagonist bicuculline and nitric-L-arginine, a nitric oxide synthase 
inhibitor,  prevented the effects of KP-13 on  passive avoidance learning and 
consolidation. The D2,D3,D4 dopamine receptor antagonist haloperidol and naloxone  
did not block the effects of KP-13. 
     These results demonstrated that the effects of KP-13 are mediated, at least in 
part, through interactions  of the α2-adrenergic, 5-HT2 serotonergic, beta-adrenergic, 
muscarinic,  cholinergic  and GABA-A-ergic , receptors and nitric oxide. 
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Fig.10. 
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Fig.11. 
 
 
 
 
 
 
 
 
 
 
Figure captions 
 
Fig.1. The action of different doses of kisspeptin-13 administered i.c.v. immediatelly 
following the learning trial on the consolidation  of passive avoidance response. Data are 
expressed as means ± S.E.M. Number in bars are the numbers of animals used. 
 
Fig.2. The effect of a nonselective α-adrenergic receptor antagonist, phenoxbenzamine 
(phenoxyb, 2 mg/kg i.p) on kisspeptin-13-induced  (1 µg/2 µl i.c.v.) consolidation of passive 
avoidance learning. Data are expressed as means ± S.E.M. Number in bars are the numbers of 
animals used. 
 
Fig.3. The effect of an α2-adrenergic receptor antagonist, yohimbine (0.5 mg /kg i.p.)  on 
kisspeptin-13- induced  (1 µg/2 µl i.c.v.) consolidation of passive avoidance learning. Data 
are expressed as means ± S.E.M. Number in bars are the numbers of animals used. 
 
Fig.4. The effect of a  β-adrenergic receptor antagonist, propranolol (10 mg/kg i.p.)   on 
kisspeptin-13-induced  (1 µg/2 µl i.c.v.) consolidation of passive avoidance learning. Data are 
expressed as means ± S.E.M. Number in bars are the numbers of animals used. 
 
Fig.5  The effect of a mixed 5-HT1/5-HT2 serotonergic receptor antagonist, methysergide (5 
mg/kg i.p.) on kisspeptin-13-induced  (1 µg/2 µl i.c.v.) consolidation of passive avoidance 
learning. Data are expressed as means ± S.E.M. Number in bars are the numbers of animals 
used. 
 
Fig.6. The effect of a nonselective 5-HT2 serotonergic receptor antagonist, cyproheptadine 
(3 mg/kg i.p.) on kisspeptin-13-induced  (1 µg/2 µl i.c.v.) consolidation of passive avoidance 
learning. Data are expressed as means ± S.E.M. Number in bars are the numbers of animals 
used. 
 
Fig.7. The effect of a nonselective muscarinic acetylcholin receptor antagonist, atropine (2 
mg/kg i.p.)  on kisspeptin-13-induced  (1 µg/2 µl i.c.v.) consolidation of passive avoidance 
learning. Data are expressed as means ± S.E.M. Number in bars are the numbers of animals 
used. 
 
Fig.8. The effect of a D2,D3,D4 dopamine receptor antagonist, haloperidol (10 ug/kg i.p.) 
on kisspeptin-13-induced  (1 µg/2 µl i.c.v.) consolidation of passive avoidance learning. Data 
are expressed as means ± S.E.M. Number in bars are the numbers of animals used. 
 
Fig.9. The effect of a γ-aminobutyric acid subunit (GABA A )receptor antagonist ,bicuculline 
(2 mg/kg i.p.) on kisspeptin-13-induced  (1 µg/2 µl i.c.v.) consolidation of passive avoidance 
learning. Data are expressed as means ± S.E.M. Number in bars are the numbers of animals 
used. 
 
Fig.10. The effect of a nonselective opioid receptor antagonist, naloxone (0.3 mg/kg i.p.) on 
kisspeptin-13-induced  (1 µg/2 µl i.c.v.) consolidation of passive avoidance learning. Data are 
expressed as means ± S.E.M. Number in bars are the numbers of animals used. 
 
Fig.11. The effect of a nitric oxide synthase inhibitor, nitro-L-arginine  (10 µg/2 µl i.c.v.) on 
kisspeptin-13-induced  (1 µg/2 µl i.c.v.) consolidation of  passive avoidance learning. Data 
are expressed as means ± S.E.M. Number in bars are the numbers of animals used. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
